

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jun 2026

An efficacy and safety comparison study of Fenofibrate and omega 3 in pediatric patients with Hypertriglyceridemia, A Randomized Clinical Trial

Protocol summary

Registration timing: **registered_while_recruiting**

Study aim

Comparison of the effects and side effects of fenofibrate and omega-3 in children with hypertriglyceridemia

Last update: **2023-01-21, 1401/11/01**

Update count: **0**

Design

The clinical trial has two intervention groups, with parallel groups, one-blind, randomized, on 60 patients, and SAS version 9 software is used for randomization with the method of 4 permutation blocks.

Registration date

2023-01-21, 1401/11/01

Settings and conduct

The study will be conducted in Rasht 17 Shahrivar hospital (endocrine department) in two intervention groups 1 and 2. The patients are not blind to the treatment group and are only researchers and statistics experts analyzing the information blind to the treatment group

Registrant information

Name

maryam shahrokhi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 13 3336 9026

Email address

mshahrokhi@gums.ac.ir

Participants/Inclusion and exclusion criteria

Inclusion criteria: children 8 to 18 years old Higher triglyceride equal to 400mg/dl Lack of pregnancy, acute or chronic pancreatitis, acute hepatitis, sepsis No alcohol consumption Absence of liver, kidney and biliary diseases Also, children with total cholesterol higher than 200 mg/dl or LDL higher than 130 mg/dl who are being treated with statins or ezetimibe will not be included

Recruitment status

Recruitment complete

Funding source

Intervention groups

The first group receives fenofibrate 100 mg once a day along with diet and the second group receives 1000 mg omega-3 twice a day. The duration of the intervention is 12 weeks and all patients are monitored weekly and monthly by pediatric endocrinologists.

Expected recruitment start date

2023-01-21, 1401/11/01

Expected recruitment end date

2023-04-21, 1402/02/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Main outcome variables

Fasting blood triglyceride

Trial completion date

empty

General information

Scientific title

An efficacy and safety comparison study of Fenofibrate and omega 3 in pediatric patients with Hypertriglyceridemia, A Randomized Clinical Trial

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20220516054879N4**

Registration date: **2023-01-21, 1401/11/01**

Public title

An efficacy and safety comparison study of Fenofibrate and omega 3 in pediatric patients with

Hypertriglyceridemia, A Randomized Clinical Trial

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

8-12 years old Patients with hypertriglyceridemia, with triglyceride more than 400mg/dl or triglyceride more than 250mg/dl that are intended to use medication or not responded to diet and exercise.

Exclusion criteria:

Patient reluctance Patient treated with statins or ezetimibe Pregnancy Acute or chronic pancreatitis

Age

From **8 years** old to **18 years** old

Gender

Both

Phase

2-3

Groups that have been masked

No information

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized

Randomization description

Type of randomization, details of any restrictions (such as blocking and block size): To randomize people in two groups, permutation blocks (of 4) are used. Considering that group A is the recipient of fenofibrate and group B is the recipient of omega-3. The randomization process will be as follows. The entire randomization file is available as an Excel file (randomization was done with SAS software version 9).

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Gilan University of Medical Sciences

Street address

Rasht-Namjo Street-Shahid Siadati Street-in front of 17 Shahrivar Hospital-Deputy for Research and Technology

City

Rasht

Province

Guilan

Postal code

4193713111

Approval date

2022-12-21, 1401/09/30

Ethics committee reference number

IR.GUMS.REC.1401.483

Health conditions studied

1

Description of health condition studied

Hypertriglyceridemia

ICD-10 code

E78.1

ICD-10 code description

Pure hyperglyceridemia, Endogenous hyperglyceridemia

Primary outcomes

1

Description

Fasting blood triglycerides

Timepoint

The variable will be measured at the beginning of the study, 8 and 12 weeks after the start of the study

Method of measurement

Blood tests

2

Description

Fasting blood LDL level

Timepoint

The variable will be measured at the beginning of the study, 8 and 12 weeks after the start of the study.

Method of measurement

Blood tests

3

Description

Fasting blood cholesterol

Timepoint

The variable will be measured at the beginning of the study, 8 and 12 weeks after the start of the study

Method of measurement

Blood tests

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group : In addition to following the diet, they also receive fenofibrate 100 mg once a day after lunch for 12 weeks.

Category

Treatment - Drugs

2**Description**

Intervention group: In addition to following the diet, they also receive 1000 mg of omega-3 twice a day for 12 weeks.

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

بیمارستان 17 شهريور

Full name of responsible person

مریم شاهروخی

Street addressRasht - Namjo Street - Shahid Siyadati Street - 17
Shahrivar Hospital**City**

Rasht

Province

Guilan

Postal code

4144654379

Phone

+98 13 3336 9019

Email

Mshahrokhi@gums.ac.ir

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Rasht University of Medical Sciences

Full name of responsible person

Mohammadreza Naghipour

Street addressRasht - Namjo Street - Shahid Siyadati Street - in front
of 17 Shahrivar Hospita**City**

Rasht

Province

Guilan

Postal code

4193713111

Phone

+98 13 3333 6394

Email

research@gums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Rasht University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Rasht University of Medical Sciences

Full name of responsible person

Maryam Shahrokhi

Position

Assistant professor

Latest degree

Specialist

Other areas of specialty/work

Medical pharmacy

Street addressRasht - Namjo Street - Shahid Siyadati Street - 17
Shahrivar Hospital**City**

Rasht

Province

Guilan

Postal code

414465379

Phone

0098133369019

Email

shahrokhi.mail85@gmail.com

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Rasht University of Medical Sciences

Full name of responsible person

Maryam Shahrokhi

Position

Assistant professor

Latest degree

Specialist

Other areas of specialty/work

Medical Pharmacy

Street addressRasht - Namjo Street - Shahid Siyadati Street - 17
Shahrivar Hospital**City**

Rasht

Province

Guilan

Postal code

4144654379

Phone

+98 13 3336 9019

Email

shahrokhi.mail85@gmail.com

Person responsible for updating data**Contact****Name of organization / entity**

Rasht University of Medical Sciences

Full name of responsible person

Parnian Nemati

Position

Pharmacy student

Latest degree

Medical doctor

Other areas of specialty/work

Medical pharmacy

Street address

Rasht-Gaz Square- Emadieh Alley- No13

City

Rasht

Province

Guilan

Postal code

4145695715

Phone

+98 919 872 6386

Email

parnianne75@gmail.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

Preservation of patients' privacy and compliance with ethical principles

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

The results of the study will be available to everyone.

Exclusive information will be available only to the treatment staff. To respect the privacy of the patient, the patient's information will be kept by the researcher.

When the data will become available and for how long

Currently, there is no plan to publish the data, but if it is published, it will be 6 months after the results are published.

To whom data/document is available

Researchers who are active in this field, pediatric specialists and scientific and qualified people

Under which criteria data/document could be used

Doctors and researchers will have the right to request, there are restrictions in order to protect the patient's privacy and comply with medical ethics

From where data/document is obtainable

17 Shahrivar Hospital, Rasht - Dr. Maryam Shahrokhi, Faculty of Pharmacy, Gilan Medical Sciences - Parnian Nemati

What processes are involved for a request to access data/document

Go to 17 Shahrivar Hospital in Rasht and sign the application form, then meet with the researcher of the plan and review the application of the referring person, consult with the ethics committee in medicine and then submit the documents.

Comments